The 3D bioprinted human induced pluripotent stem cell-derived cardiac model : Toward functional and patient-derived in vitro models for disease modeling and drug screening

More relevant human tissue models are needed to produce reliable results when studying disease mechanisms of genetic diseases and developing or testing novel drugs in cardiac tissue engineering (TE). Three-dimensional (3D) bioprinting enables physiologically relevant positioning of the cells inside the growth matrix according to the detailed digital design. Here we combined human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) with methacrylated gelatin (GelMA) and collagen I-based bioink and 3D extrusion bioprinted a cardiac in vitro model for disease modeling and drug screening. Bioprinted constructs were characterized for their rheological properties, swelling behavior, degradation, as well as shape fidelity. The printed structures demonstrated good mechanical properties and high shape fidelity upon culture. Immunocytochemistry revealed elongated hiPSC-CMs growing inside the structures and the presence of the connexin 43 marker, indicating cardiac gap junctions between printed cells and tissue formation. Extensive functional analyses with calcium imaging showed normal functionality and calcium-handling properties for hiPSC-CMs. Finally, suitability of this 3D bioprinted construct for patient-specific disease modeling was demonstrated by bioprinting hiPSC-CMs from a patient carrying an inherited gene mutation causing catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT hiPSC-CMs responded to adrenaline treatment in the 3D bioprinted model in a manner that is characteristic for CPVT disease specific phenotype. Thus, the 3D bioprinted hiPSC-CM in vitro model has great potential for disease modeling and drug screening in cardiac tissue engineering.Peer reviewe

Hyvä näytteenotto keuhkosyövän diagnostiikassa ja levinneisyyden arviossa

Teema : keuhkosyövän diagnostiikka ja hoito. English summaryPeer reviewe

Common Inflammation-Related Candidate Gene Variants and Acute Kidney Injury in 2647 Critically Ill Finnish Patients

Acute kidney injury (AKI) is a syndrome with high incidence among the critically ill. Because the clinical variables and currently used biomarkers have failed to predict the individual susceptibility to AKI, candidate gene variants for the trait have been studied. Studies about genetic predisposition to AKI have been mainly underpowered and of moderate quality. We report the association study of 27 genetic variants in a cohort of Finnish critically ill patients, focusing on the replication of associations detected with variants in genes related to inflammation, cell survival, or circulation. In this prospective, observational Finnish Acute Kidney Injury (FINNAKI) study, 2647 patients without chronic kidney disease were genotyped. We defined AKI according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. We compared severe AKI (Stages 2 and 3, n = 625) to controls (Stage 0, n = 1582). For genotyping we used iPLEX(TM) Assay (Agena Bioscience). We performed the association analyses with PLINK software, using an additive genetic model in logistic regression. Despite the numerous, although contradictory, studies about association between polymorphisms rs1800629 in TNFA and rs1800896 in IL10 and AKI, we found no association (odds ratios 1.06 (95% CI 0.89-1.28, p = 0.51) and 0.92 (95% CI 0.80-1.05, p = 0.20), respectively). Adjusting for confounders did not change the results. To conclude, we could not confirm the associations reported in previous studies in a cohort of critically ill patients.Peer reviewe

Heme oxygenase-1 repeat polymorphism in septic acute kidney injury

Acute kidney injury (AKI) is a syndrome that frequently affects the critically ill. Recently, an increased number of dinucleotide repeats in the HMOX1 gene were reported to associate with development of AKI in cardiac surgery. We aimed to test the replicability of this finding in a Finnish cohort of critically ill septic patients. This multicenter study was part of the national FINNAKI study. We genotyped 300 patients with severe AKI (KDIGO 2 or 3) and 353 controls without AKI (KDIGO 0) for the guanine-thymine (GTn) repeat in the promoter region of the HMOX1 gene. The allele calling was based on the number of repeats, the cut off being 27 repeats in the S-L (short to long) classification, and 27 and 34 repeats for the S-M-L2 (short to medium to very long) classification. The plasma concentrations of heme oxygenase-1 (HO-1) enzyme were measured on admission. The allele distribution in our patients was similar to that published previously, with peaks at 23 and 30 repeats. The S-allele increases AKI risk. An adjusted OR was 1.30 for each S-allele in an additive genetic model (95% CI 1.01-1.66; p = 0.041). Alleles with a repeat number greater than 34 were significantly associated with lower HO-1 concentration (p<0.001). In septic patients, we report an association between a short repeat in HMOX1 and AKI risk